home

Novel agent improves myocardial perfusion imaging in patients with obesity

Frontierhealio2016-04-20 11:18 Read   78

A novel PET agent for myocardial perfusion imaging had better sensitivity than and similar specificity to myocardial perfusion imaging with single-photon emission CT in patients with obesity, according to recent study findings.

Similar RA disease response seen with abatacept, adalimumab at more than 2 years

Commentshealio2016-04-20 11:12 Read   207

With background methotrexate treatment, similar response rates were seen between patients with rheumatoid arthritis who were treated with the biologic medications abatacept or adalimumab, according to recently published data.

Weekly Market Movers: Asia Analysis (to 18 Apr 2016)

Commentsepvantage2016-04-20 10:50 Read   77

EvaluatePharma’s EventAnalyzer Asia delivers a weekly round up of key events driving company valuations in Asia.

AB Science claims a positive result in masitinib ALS study

Trendepvantage2016-04-20 10:45 Read   116

France’s AB Science seems to have notched up an unexpected positive interim readout in a phase III study with its c-KIT inhibitor, masitinib, in the difficult indication of amyotrophic lateral sclerosis (ALS).

Ready Or Not: Next Alzheimer’s Drugs Might Strain Health Systems

Commentsxconomy2016-04-20 10:36 Read   71

By 2029, more than 20 percent of people in the United States will be over the age of 65. That’s why the race to find effective treatments for Alzheimer’s disease feels urgent.

Atara Bio’s Collaborator QIMR Berghofer Medical Research Institute Reports Positive Clinical Data for T Cell Immunotherapy in Nasopharyngeal Cancer (NPC), a Solid Tumor

EVENTSFIRST WORD2016-04-20 10:25 Read   74

Results Highlighted in Oral Presentation at the 2016 American Association for Cancer Research (AACR) Annual Meeting

Bristol-Myers Squibb's PD-1 inhibitor Opdivo prolongs survival in head and neck cancer: study

TrendFIRSTWORD2016-04-20 10:20 Read   90

Study data presented Tuesday at the American Association for Cancer Research (AACR) annual meeting showed that Bristol-Myers Squibb's Opdivo (nivolumab) conferred a survival benefit in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) after platinum therapy, compared with three standard of care options.

'Palliative Care' Gets a Bad Rap, Study Finds

CommentsDRUGS2016-04-20 10:12 Read   75

The term "palliative care" triggers negative feelings among many cancer patients, and needs "rebranding," researchers say.

Americans' Longer Life = Poorer Health

CommentsDRUGS2016-04-20 10:04 Read   67

Americans are living longer, but those extra years may include poor health or a disability, a new study finds.

FDA launches first ad campaign focused on dangers of smokeless tobacco among rural teens

RegulatorFDA2016-04-20 09:58 Read   108

The U.S. Food and Drug Administration announced today it is expanding its award-winning “The Real Cost” campaign to educate rural, white male teenagers about the negative health consequences associated with smokeless tobacco use.

Unfazed by a tough market, PhaseRx, Gemphire go for IPOs

EVENTSfiercebiotech2016-04-20 09:53 Read   76

Two biotechs are seeking to float in two separate offerings worth $90 million as both look to shrug off the bad luck of other companies that had to ditch their IPOs in the past week.

Sucampo Reports Top-Line Data from Phase 2a Study of Cobiprostone in Patients with PPI-Refractory Non-Erosive Reflux Disease (NERD) and Symptomatic Gastroesophageal Reflux Disease (sGERD)

TrendYAHOO2016-04-20 09:49 Read   100

Sucampo Pharmaceuticals, Inc. (Sucampo) (SCMP), a global biopharmaceutical company, today announced top-line data from a Phase 2a study of cobiprostone in patients with proton pump inhibitor (PPI)-refractory non-erosive reflux disease (NERD) or symptomatic gastroesophageal reflux disease (sGERD).